Published Technical Disclosure Archive

Multimodal Molecular Imaging and Therapy Platform

Publication ID: 24-11857648_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Multimodal Molecular Imaging and Therapy Platform,” Published Technical Disclosure No. 24-11857648_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857648_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,648.

Summary of the Inventive Concept

A next-generation platform for personalized medicine, integrating targeted molecular imaging and therapy compounds, real-time monitoring, and adaptive treatment optimization, enabling precise and effective disease diagnosis and treatment.

Background and Problem Solved

The original patent disclosed a multivalent molecular imaging and/or targeted drug delivery method, but it had limitations in terms of real-time monitoring and adaptive treatment optimization. The new inventive concept addresses these limitations by introducing a multimodal platform that co-administers targeted molecular imaging and therapy compounds, enabling real-time monitoring and adaptive treatment optimization.

Detailed Description of the Inventive Concept

The multimodal platform consists of a targeted molecular imaging compound and a targeted therapeutic compound, designed to target the same biomarker on a biological subject. The platform enables real-time monitoring of the biological subject using a detection device, and the detection data is used to optimize the administration of the targeted therapeutic compound. The platform can be used for personalized medicine, where the targeted molecular imaging compound is administered to a biological subject, detected using a detection device, and the detection data is used to select a targeted therapeutic compound for treating the biological subject.

Novelty and Inventive Step

The new inventive concept introduces the concept of real-time monitoring and adaptive treatment optimization, which is not present in the original patent. The co-administration of targeted molecular imaging and therapy compounds, and the use of detection data to optimize treatment, are novel and non-obvious features that provide a significant improvement over the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the multimodal platform could include the use of different types of detection devices, such as MRI or PET scanners, or the use of different types of targeted molecular imaging and therapy compounds. Variations of the platform could also include the integration of artificial intelligence or machine learning algorithms to optimize treatment based on detection data.

Potential Commercial Applications and Market

The multimodal platform has significant commercial potential in the fields of personalized medicine, cancer treatment, and molecular imaging. The platform could be used in hospitals and research institutions, and could be marketed to pharmaceutical companies and biotechnology companies developing targeted therapies.

CPC Classifications

SectionClassGroup
A A61 A61K51/082
A A61 A61K9/51
A A61 A61K47/6893
A A61 A61K51/1027
C C07 C07D255/02
C C07 C07D257/02
C C07 C07K7/06
C C07 C07K7/64
C C07 C07K16/30
G G01 G01N33/5008
G G01 G01N33/60
C C07 C07K2319/00

Field of Art

Molecular imaging, radiopharmaceuticals, and targeted therapeutic compounds, involving interdisciplinary expertise in chemistry, molecular biology, nuclear medicine, and pharmaceutical engineering

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degree (PhD) in chemistry or molecular biology, experienced in designing molecular imaging agents, understanding chelation strategies, and developing targeted therapeutic compounds with expertise in radioisotope labeling techniques

Obviousness Rationale

A PHOSITA would recognize that the PTD's multimodal platform represents a predictable extension of the source patent's molecular imaging and therapy strategies by introducing real-time monitoring and adaptive treatment optimization as a logical progression of existing targeted molecular imaging technologies. The combination of molecular imaging compounds with therapeutic compounds and feedback-driven treatment adjustment represents an incremental innovation that would be obvious to a skilled practitioner familiar with personalized medicine approaches. The technical elements are fundamentally consistent with the source patent's foundational molecular targeting and labeling strategies.

Obvious Combinations & Variations

Source Patent Element
Molecular imaging compounds with chelators and detectable labels
PTD Variation
Real-time monitoring system integrating detection devices and adaptive treatment protocols
Obviousness Reasoning
Known technique of expanding diagnostic imaging technologies to include treatment optimization, representing a predictable application of existing molecular imaging principles
Source Patent Element
Peptide-based targeting compounds with radionuclide or dye labels
PTD Variation
Co-administration of molecular imaging and therapeutic compounds targeting identical biomarkers
Obviousness Reasoning
Finite identified solution for improving diagnostic and therapeutic precision, utilizing well-established molecular targeting strategies
Source Patent Element
Chelation strategies involving NOTA, DOTA, and other metal-binding cores
PTD Variation
Integration of computational analysis and machine learning for treatment optimization
Obviousness Reasoning
Predictable technological progression applying computational techniques to existing molecular imaging frameworks
Source Patent Element
Multimodal molecular compounds for imaging and therapy
PTD Variation
Personalized medicine platform with adaptive treatment selection based on real-time imaging data
Obviousness Reasoning
Logical extension of existing targeted molecular imaging technologies, representing an incremental innovation in precision medicine approaches
Source Patent Element
Radionuclide and dye labeling techniques
PTD Variation
Multimodal detection devices including MRI and PET scanning integration
Obviousness Reasoning
Known technique of expanding detection modalities, representing a design choice within established medical imaging paradigms
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the instant publication would have been obvious to a person having ordinary skill in the art at the time of the invention, with reasonable expectation of success, when considered in light of US Patent 11857648. The disclosed multimodal molecular imaging and therapy platform represents a predictable combination of known techniques in molecular targeting, imaging, and personalized treatment strategies, thereby rendering potential patent claims obvious and anticipatable by the prior art.

Original Patent Information

Patent NumberUS 11,857,648
TitleDimerization strategies and compounds for molecular imaging and/or radioimmunotherapy
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION